NLS Pharmaceutics Ltd. Logo

NLS Pharmaceutics Ltd.

Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.

NLSP | US

Overview

Corporate Details

ISIN(s):
CH0523961370 (+1 more)
LEI:
Country:
United States of America
Address:
THE CIRCLE 6, 0 ZURICH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders. The company is actively developing treatments for sleep-wake disorders, with a particular focus on narcolepsy, aiming to provide safer and more effective therapies to address significant unmet medical needs. NLS Pharmaceutics advances its pipeline of novel CNS therapies and engages in strategic collaborations to develop next-generation treatments, including gene-edited cell therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:15
Foreign Filer Report
6-K - NewcelX Ltd. (0001783036) (Filer)
English 17.3 KB

Automate Your Workflow. Get a real-time feed of all NLS Pharmaceutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NLS Pharmaceutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NLS Pharmaceutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America MRKR

Talk to a Data Expert

Have a question? We'll get back to you promptly.